Although its exact mechanism of action is not fully understood, it is believed to work by suppressing appetite, preventing excess fat storage, reducing particular fat and cholesterol levels, and potentially influencing the brain's reward system to reduce binge eating
Wegovy's most common adverse effects involve the digestive system, with nausea reported in approximately 2044% of patients and vomiting in 924%, depending on the dose, according to clinical trials and the SmPC
Consistency is important, as results are gradual over several weeks of continuous use
These often improve with continued use
Triple-agonist means targeting GLP-1, GIP, and glucagon receptors
GLP-1 medications require review and approval by a licensed healthcare professional